Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
Smith VM., Lomas O., Constantine D., Palmer L., Schuh AH., Bruce D., Gonchar O., Macip S., Jayne S., Dyer MJS., Eyre TA.
Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses. In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.